[go: up one dir, main page]

CO4940506A1 - DERIVATIVES OF 9-OXYME ERYTHROMYCIN - Google Patents

DERIVATIVES OF 9-OXYME ERYTHROMYCIN

Info

Publication number
CO4940506A1
CO4940506A1 CO98033538A CO98033538A CO4940506A1 CO 4940506 A1 CO4940506 A1 CO 4940506A1 CO 98033538 A CO98033538 A CO 98033538A CO 98033538 A CO98033538 A CO 98033538A CO 4940506 A1 CO4940506 A1 CO 4940506A1
Authority
CO
Colombia
Prior art keywords
alkyl
integer
optionally substituted
formula xvi
ring
Prior art date
Application number
CO98033538A
Other languages
Spanish (es)
Inventor
Wu Tong-Jin
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO4940506A1 publication Critical patent/CO4940506A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un compuesto de la fórmula 1 o una sal farmacéuticamenteaceptable del mismo, en la que X es -CR7 R8 -o-NR7 -; o X es junto con R2 forma N=CR4 R5 ; o X y R2 juntos forman un anillo heterocíclico de fórmula XVI:En la que dicho anillo de fórmula XVI, r y p son cada uno de ellos independientemente un número entero de 1 a 3, q es O ó 1 y X1 es -CH2 -, O, -C(O)-, -C(S)-, -CH=CH-, CH(OH)CH(OH)-, o -NH-; y donde las partes (CH2 )r y (CH2 )p de dicho anillo de fórmula XVI están opcionalmente sustituidas con 1 a 4 sustituyentes y el átomo de nitrógeno cuando X1 es -NH- está opcionalmente sustituido con 1 sustituyente, estando dichos sustituyentes opcionales independientemente seleccionados entre el grupo constituido por -C(O) o (alquilo C1 -C10 ), alcoxi C1 -C10 , alcanoílo C1 -C10 , halógeno, nitro, ciano, heterociclilo de 5-10 elementos, alquilo C1 -C10 , -NR7 R8 , arilo C6 -C10 , -S(O)n (alquilo C1 -C10 ) donde n es un número entero de 0 a 2, y -SO2 NR7 R8 ; R1 es H o alquilo C1 -C10 , donde 1 a 3 carbonos de dicho alquilo están opcionalmente remplazados por un hetero+atomo seleccionado entre O, S y N, estando dicho alquilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente entre el grupo constituido por -C(O) O (alquilo C1 -C10 ), alcoxi C1 -C10 , alcanoílo C1 -C10 , halógeno, nitro, ciano, heterociclilo de 5-10 elementos, alquilo C1 -C10 , -NR7 R8 , arilo C1 -C10 , -S(O)n (alquilo C1 -C10 ) donde n es un número entero de 0 a 2 , y -SO2 NR7 R8 ; R2 es (y) H; R4 , -C(=)R4 , -C(O)OR4 , o -(CR7 R8 )m R3 cuando X es -NR7 -, o (II) H, R4 , o -CR7 R8 -, donde para ambos (i) y (ii) m es un número entero de 0 a 6 y tanto R7 como R8 pueden variar en cada caso en que m sea mayor que 1;...A compound of formula 1 or a pharmaceutically acceptable salt thereof, wherein X is -CR7 R8 -o-NR7 -; or X is together with R2 form N = CR4 R5; or X and R2 together form a heterocyclic ring of formula XVI: Wherein said ring of formula XVI, r and p are each independently an integer from 1 to 3, q is O or 1 and X1 is -CH2 -, O , -C (O) -, -C (S) -, -CH = CH-, CH (OH) CH (OH) -, or -NH-; and where the (CH2) r and (CH2) p parts of said ring of formula XVI are optionally substituted with 1 to 4 substituents and the nitrogen atom when X1 is -NH- is optionally substituted with 1 substituent, said optional substituents being independently selected between the group consisting of -C (O) or (C1-C10 alkyl), C1-C10 alkoxy, C1-C10 alkanoyl, halogen, nitro, cyano, 5-10-membered heterocyclyl, C1-C10 alkyl, -NR7 R8, C6 -C10 aryl, -S (O) n (C1-C10 alkyl) where n is an integer from 0 to 2, and -SO2 NR7 R8; R1 is H or C1-C10 alkyl, where 1 to 3 carbons of said alkyl are optionally replaced by a hetero + atom selected from O, S and N, said alkyl being optionally substituted with 1 to 3 substituents independently selected from the group consisting of -C (O) O (C1-C10 alkyl), C1-C10 alkoxy, C1-C10 alkanoyl, halogen, nitro, cyano, 5-10 membered heterocyclyl, C1-C10 alkyl, -NR7 R8, C1-C10 aryl, -S (O) n (C1-C10 alkyl) where n is an integer from 0 to 2, and -SO2 NR7 R8; R2 is (y) H; R4, -C (=) R4, -C (O) OR4, or - (CR7 R8) m R3 when X is -NR7 -, or (II) H, R4, or -CR7 R8 -, where for both (i ) and (ii) m is an integer from 0 to 6 and both R7 and R8 may vary in each case where m is greater than 1; ...

CO98033538A 1997-06-11 1998-06-11 DERIVATIVES OF 9-OXYME ERYTHROMYCIN CO4940506A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4934997P 1997-06-11 1997-06-11

Publications (1)

Publication Number Publication Date
CO4940506A1 true CO4940506A1 (en) 2000-07-24

Family

ID=21959341

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98033538A CO4940506A1 (en) 1997-06-11 1998-06-11 DERIVATIVES OF 9-OXYME ERYTHROMYCIN

Country Status (31)

Country Link
EP (1) EP0988308A1 (en)
JP (1) JP2000513026A (en)
KR (1) KR20010013660A (en)
CN (1) CN1259135A (en)
AP (1) AP9801253A0 (en)
AR (1) AR012244A1 (en)
AU (1) AU7226798A (en)
BG (1) BG103947A (en)
BR (1) BR9810021A (en)
CA (1) CA2293335A1 (en)
CO (1) CO4940506A1 (en)
CZ (1) CZ9904388A3 (en)
EA (1) EA199901016A1 (en)
GT (1) GT199800074A (en)
HN (1) HN1998000073A (en)
HR (1) HRP980316A2 (en)
HU (1) HUP0002252A3 (en)
ID (1) ID24529A (en)
IL (1) IL132767A0 (en)
IS (1) IS5251A (en)
MA (1) MA26505A1 (en)
NO (1) NO996108L (en)
OA (1) OA11225A (en)
PA (1) PA8451801A1 (en)
PE (1) PE79899A1 (en)
PL (1) PL337606A1 (en)
TN (1) TNSN98083A1 (en)
TR (1) TR199902995T2 (en)
TW (1) TW448174B (en)
WO (1) WO1998056800A1 (en)
ZA (1) ZA985018B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1998000159A (en) * 1997-10-29 1999-02-09 Monsanto Co DERIVATIVES OF 9- AMINO - 3 CETO ERITROMICINA
AU5299499A (en) * 1998-09-22 2000-04-10 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
FR2786188B1 (en) * 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
US6258785B1 (en) 1998-12-02 2001-07-10 Pfizer Inc. Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin
EP1298138B1 (en) * 1998-12-10 2006-11-02 Pfizer Products Inc. Carbamate and Carbazate Ketolide Antibiotics
US6284732B1 (en) * 1998-12-18 2001-09-04 Bio-Rad Laboratories, Inc. Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
WO2000063225A2 (en) * 1999-04-16 2000-10-26 Kosan Biosciences, Inc. Macrolide antiinfective agents
SK15162001A3 (en) 1999-05-24 2003-02-04 Pfizer Products Inc. 13-Methyl-erythromycin derivatives
PT1181300E (en) * 1999-06-07 2004-02-27 Abbott Lab DERIVATIVES 6-O-CARBAMATE OF CETOLID
ID27331A (en) * 1999-09-29 2001-03-29 Pfizer Prod Inc MAKING ANTIBIOTIC-ANTIBIOTIC KETOLIDA CARBAMATE
EP1114826A3 (en) * 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
EP1439186A3 (en) * 1999-12-29 2004-11-03 Pfizer Products Inc. Intermediates for novel antibacterial and prokinetic macrolides
US6946446B2 (en) 2000-02-24 2005-09-20 Abbott Laboratories Anti-infective agents useful against multidrug-resistant strains of bacteria
US6403776B1 (en) 2000-07-05 2002-06-11 Pfizer Inc. Synthesis of carbamate ketolide antibiotics
WO2003090761A1 (en) * 2002-04-25 2003-11-06 Abbott Laboratories 9-oxime macrolide antibacterials
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
WO2004080391A2 (en) * 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
JP5383037B2 (en) 2004-02-27 2014-01-08 リブ−エックス ファーマシューティカルズ,インコーポレイテッド Macrocyclic compounds and methods of making and using them
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2010048600A1 (en) 2008-10-24 2010-04-29 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN108310000A (en) 2009-09-10 2018-07-24 森普拉制药公司 Treat malaria, the method for tuberculosis and MAC diseases
CN102146085B (en) * 2010-02-09 2014-03-26 北京理工大学 9-oxime-ether ketolide derivative, and preparation method and medical composite thereof
KR20180101643A (en) 2010-03-22 2018-09-12 셈프라 파마슈티컬스, 인크. Crystalline forms of a macrolide, and uses therefor
CA2799937A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
CA2868262A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
AU2014239959A1 (en) 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5527780A (en) * 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2718450B1 (en) * 1994-04-08 1997-01-10 Roussel Uclaf New erythromycin derivatives, their preparation process and their use as drugs.

Also Published As

Publication number Publication date
EA199901016A1 (en) 2000-06-26
CZ9904388A3 (en) 2002-10-16
EP0988308A1 (en) 2000-03-29
TW448174B (en) 2001-08-01
MA26505A1 (en) 2004-12-20
OA11225A (en) 2003-07-17
NO996108D0 (en) 1999-12-10
AU7226798A (en) 1998-12-30
ZA985018B (en) 1999-12-10
TR199902995T2 (en) 2000-02-21
PL337606A1 (en) 2000-08-28
ID24529A (en) 2000-07-20
BG103947A (en) 2000-07-31
IS5251A (en) 1999-11-16
HRP980316A2 (en) 1999-04-30
IL132767A0 (en) 2001-03-19
WO1998056800A1 (en) 1998-12-17
TNSN98083A1 (en) 2005-03-15
KR20010013660A (en) 2001-02-26
PA8451801A1 (en) 2000-05-24
JP2000513026A (en) 2000-10-03
GT199800074A (en) 1999-11-27
NO996108L (en) 2000-02-10
HUP0002252A2 (en) 2000-12-28
PE79899A1 (en) 1999-08-25
AP9801253A0 (en) 1999-12-04
HN1998000073A (en) 1999-01-08
CN1259135A (en) 2000-07-05
HUP0002252A3 (en) 2002-01-28
AR012244A1 (en) 2000-09-27
CA2293335A1 (en) 1998-12-17
BR9810021A (en) 2000-09-19

Similar Documents

Publication Publication Date Title
CO4940506A1 (en) DERIVATIVES OF 9-OXYME ERYTHROMYCIN
ECSP034611A (en) AMINOTIAZOLES AND ITS USE AS ADENOSINE RECEIVER ANTAGONISTS
ECSP034475A (en) DERIVATIVES OF 4-PHENYL-PIRIDIN AS ANTAGONISTS OF THE NEUROQUININE RECEIVER-1
MX9705590A (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
NO20022317L (en) Triphenylalkylene derivatives and their use as selective estrogen receptor modulates
HRP20000835B1 (en) ISOTHIAZOL DERIVATIVES USED AS ANTITUMOR AGENTS
ES2111237T3 (en) BENZENE SULFONAMIDE DERIVATIVES AND PREPARATION PROCEDURE.
ES2132373T3 (en) BENZOCICLOHEPTENOS, BENZOXEPINAS AND BENZOTIEPINAS.
ES447509A1 (en) IMPROVEMENTS IN SHOCK ABSORBERS-SPACERS FOR SUSPENDED CA-BLES.
AR009413A1 (en) A COMPOUND, WHICH IS A DERIVATIVE OF BENZOHETEROCICLICO DISTAMICINA, ITS USE, A PROCEDURE TO PRODUCE IT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
ID21568A (en) NEW USE FOR DOWN-1,3-PROPANADIOL
CO4650117A1 (en) BENCILSULFIDE DERIVATIVES AND PROCESS FOR ITS PRODUCTION.
PE20010750A1 (en) SPIRO DERIVATIVES [2H-1-BENZOPYRAN-2,4`-PIPERIDINE]
PT1064281E (en) BENZO-HETEROCYCLIC DISTAMICINE DERIVATIVES PROCESS FOR THE PREPARATION AND THEIR USE AS ANTITUMATIC AGENTS
EA199800987A1 (en) BENZOXAZINOUS ANTAGONISTS OF DOPAMINE D4 RECEPTOR
MX9605366A (en) BICYCLE AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHETIC.
AR007108A1 (en) ANTI-TUMOR AND ANTIVIRAL RENTAL AGENTS, PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH AGENTS.
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism
CO5200762A1 (en) PREPARATION OF PIPERIDIN-4-SUBSTITUTED WAVES
DK1381370T3 (en) N-Biphenylcarbonyl- and N-phenylpyridylcarbonyl-substituted bicyclic and tricyclic azepines and diazepines as vasopressin agonists
AR036734A1 (en) DERIVATIVES OF 8-AMINO- [1,2,4] TRIAZOLO [1,5-A] PIRIDINA-6-CARBOXILICO
ATE168686T1 (en) N,N'-DISUBSTITUTED AMIDE DERIVATIVES
ES447751A1 (en) PROCEDURE FOR PREPARING IMIDAZOLILQUINAZOLINE DERIVATIVES.
FI902775A0 (en) ARYLOXI-, ARYLTIO-, HETEROARYLOXI-, HETEROARYLTIO-ALKYLENDERIVAT AV AMINER.
GB1103875A (en) Dibenzocycloheptadiene derivatives and their preparation